Skip to main menu
Skip to search page
Skip to main content area
Skip to footer menu
Close
Font Resize
A-
A+
Reset font size
Keyboard navigation
Highlight Links
Clear cookies
Images Greyscale
Close
Search
Website Menu
CONTACT US
עברית
About
Company Profile & Milestones
Leadership
Capabilities
Partnerships
Social Responsibility
Working at Kamada
Products
Proprietary
Distribution
Science
Therapeutic Focus Areas
Pipeline
AAT Mechanism Of Action
Investors & Media
News
Events & Presentations
Stock Information
Financial Reports
SEC Filings
Corporate Governance
Investor Resources
About
Company Profile & Milestones
Leadership
Capabilities
Partnerships
Social Responsibility
Working at Kamada
Products
Proprietary
Distribution
Science
Therapeutic Focus Areas
Pipeline
AAT Mechanism Of Action
Investors & Media
News
Events & Presentations
Stock Information
Financial Reports
SEC Filings
Corporate Governance
Investor Resources
Contact Us
עברית
Updated company presentation
Join Our Mailing List
Sign up to receive Email updates from Kamada
Latest News
Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
Dec. 16, 2019
This website uses cookies to track the site’s performance and improve user experience.
By using our website you consent to all cookies in accordance with our
Privacy Policy
.
I Agree
